The long-term objective of our research program is to understand the pathogenesis of human bladder cancer with the hope that this information will be valuable for bladder cancer prevention, diagnosis, prognosis, or treatment. The immediate goal of the present application is to determine the biological, biochemical, and genetic consequences of p53 loss in multistep chemical transformation of human uroepithelial cells (HUC). The rationale for studying the effects of p53 loss early in HUC transformation is based on observations that TP53 is the most commonly mutated tumor suppressor gene in clinical bladder cancers and its loss correlates with invasive cancers and a poor clinical prognosis. It has been hypothesized that p53 loss leads to genome instability at both the DNA and chromosome levels. However, direct experimental evidence in a human epithelial system associating p53 loss of function with chromosome instability, increased DNA mutability, or tumor progression is lacking. In this research, the predicted phenotypes for p53 loss of function will be tested. For these studies, we have established a unique new in vitro transformation system consisting of an isogeneic series of HUC cell lines immortalized after transformation in vitro with Human Papilloma Virus 16 E6 or E7 genes. E6 binds wildtype (wt) p53 leading to rapid p53 degradation, while E7 binds and alters Hb (and other proteins). Thus, the E6-HUC mimic HUC that have sustained a TP53 mutation early in tumorigenesis, while the E7-HUC represent HUC that have not yet acquired such a change. We will answer the following specific questions: (1) Do transdominant p53 mutants (p53TDM) that override (wt)p53 generate chromosome instability? (2) What is the biological significance of the genetic alterations associated with immortalization? (3) Does loss of (wt)p53 function potentiate spontaneous or carcinogen induced mutability? (4) Is TP53 a target gene for arylamine mutagenesis in HUC immortalization or tumorigenic transformation? The significance of these studies is that they directly address fundamental and timely questions concerning the biological and biochemical consequence of an early or late loss of p53 function in the pathogenesis of human bladder cancer. Furthermore, they will elucidate mechanisms by which HPV16 E6 and E7 genes contribute to transformation of urogenital epithelium.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA067158-01
Application #
2110753
Study Section
Metabolic Pathology Study Section (MEP)
Project Start
1995-04-01
Project End
1999-01-31
Budget Start
1995-04-01
Budget End
1996-01-31
Support Year
1
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of Wisconsin Madison
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Sarkar, S; Julicher, K P; Burger, M S et al. (2000) Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers. Cancer Res 60:3862-71
Cuthill, S; Agarwal, P; Sarkar, S et al. (1999) Dominant genetic alterations in immortalization: role for 20q gain. Genes Chromosomes Cancer 26:304-11
Vieten, L; Belair, C D; Savelieva, L et al. (1998) Minimal deletion of 3p13-->14.2 associated with immortalization of human uroepithelial cells. Genes Chromosomes Cancer 21:39-48
Yeager, T R; Reznikoff, C A (1998) Methotrexate resistance in human uroepithelial cells with p53 alterations. J Urol 159:581-5
Belair, C D; Yeager, T R; Lopez, P M et al. (1997) Telomerase activity: a biomarker of cell proliferation, not malignant transformation. Proc Natl Acad Sci U S A 94:13677-82
Reznikoff, C A; Belair, C D; Yeager, T R et al. (1996) A molecular genetic model of human bladder cancer pathogenesis. Semin Oncol 23:571-84
Puthenveettil, J A; Frederickson, S M; Reznikoff, C A (1996) Apoptosis in human papillomavirus16 E7-, but not E6-immortalized human uroepithelial cells. Oncogene 13:1123-31
Reznikoff, C A; Yeager, T R; Belair, C D et al. (1996) Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells. Cancer Res 56:2886-90